Effects of Levetiracetam on the Content of Neurotransmitter Amino Acids in the Brain of Rats with the Audiogenic Epileptiform Siezures



Citar

Texto integral

Resumo

The anticonvulsant action of novel antiepileptic drug levetiracetam (LVT) on the content of aspartate, glutamate, glycine, taurine and GABA in brain structures of Krushinsky-Molodkina (KM) rats were studied using HPLC/FD techniques. The treatment with LVT anticipated decrease of levels of glutamate, glycine and taurine produced by seizure attack. In medulla oblongata LVT prevented the elevation of GABA level induced by the audiogenic stress. Thus, the anticonvulsant action of LVT against audiogenic seizures is likely to be related to the normalizing effect upon the levels of both excitatory and inhibitory neurotransmitter amino acid in the frontal cortex and medulla oblongata of KM rats.

Sobre autores

Lyudmila Malikova

Email: ludmal2006@yandex.ru

Irina Fedotova

Petr Klodt

Natal'ya Surina

Inga Poletaeva

Vladimir Kudrin

Kirill Raevskiy

L Malikova

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

I Fedotova

Lomonosov State University

; Lomonosov State University

P Klodt

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

N Surina

Lomonosov State University

; Lomonosov State University

V Kudrin

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

I Poletaeva

Lomonosov State University

; Lomonosov State University

K Rayevsky

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

Zakusov Institute of Pharmacology Russian Academy of Medical Sciences

Bibliografia

  1. Бадалян О.Л., Бурд С.Г., Савенков А.А. и др. Оптимизация фармакотерапии эпилепсии. Возможности применения габапентина. // Неврология. 2006. Т. 14, № 9. С. 710-713.
  2. Калинин В.В. Препарат леветирацетам (кеппра) в эпилептологии. // Ж. неврол. и психиат. 2007. Т. 107, № 3. С. 74-77.
  3. Карлов В.А., Власов П.Н. Эффективность кеппры в составе комплексной терапии при фармакорезистентной эпилепсии у взрослых. // Ж. неврол. и психиат. 2005. № 7. С. 40-44.
  4. Маликова Л.А., Федотова И.Б., Полетаева И.И., Раевский К.С. Противосудорожное действие леветирацетама при аудиогенных эпилептиформных припадках у крыс Крушинского-Молодкиной. // Эксперим. и клин. фармакол. 2007. Т. 70, № 6. С. 3-5.
  5. Раевский К.С., Маликова Л.А., Калинин В.А. Нейрональные и нейрохимические механизмы действия нового антиэпилептического препарата леветирацетама. // Эксперим. и клин. фармакол. 2007. Т. 70, № 2. С. 70-74.
  6. Семиохина А.Ф., Федотова И.Б., Полетаева И.И. Крысы линии Крушинского-Молодкиной: исследования аудиогенной эпилепсии, сосудистой патологии и поведения. // Ж. высш. нерв. деят. 2006. Т. 56, № 3. С. 298-316.
  7. Энциклопедия лекарств. Ежегодный сборник. М.: «РЛС-2007», 2006.
  8. Hanon E., Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. // Seizure. 2001. Vol. 10, N 4. P. 287-293.
  9. De Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. // CNS Drug Rev. 2007. Vol. 13, N 1. P. 43-56.
  10. De Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. // CNS Drug Rev. 2007. Vol. 13, N 1. P. 57-78.
  11. Dedeurwaerdere S., Vonck K., De Herdt V., et al. Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy. // Acta Neurol. Belg. 2006. Vol. 106, N 2. P. 91-97.
  12. Dufour F, Nalecz K.A., Nalecz M.J., Nehlig A. Modulation of absence seizures by branched-chain amino acids: correlation with brain amino acid concentrations. // Neurosci. Res. 2001. Vol. 40, N 3. P. 255-263.
  13. Lynch B.A., Lambeng N., Nocka, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101, N 26. P. 9861-9866.
  14. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. // Eur.J. Pharmacol. 1998. Vol. 353 (2-3). P. 191-206.
  15. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? // Epilepsia. 2001. Vol. 42, N 4. P. 13-18
  16. Meurs A., Clinckers R., Ebinger G., et al. Seizure activity and changes in hippocampal extracellular glutamate, GABA, dopamine and serotonin. // Epilepsy Res. 2008. Vol. 78, N 1. P. 50-59.
  17. Pearson S.J., et al. Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable o-phtalaldehyde-sulphite derivatives. // J. Neuronal. Transm. 1991. Vol. 86. P. 151-157.
  18. Popova L.D. The influence of kynurenic acid on the content of excitatory and inhibitory mediators in rats with different levels of seizure susceptibility. // Ukr. Biokhim Zh. 2006. Vol. 78, N 5. P. 120-126.
  19. Sills G.J., Leach J.P., Fraser C.M., et al. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. // Eur.J. Pharmacol. 1997. Vol. 325, N 1. P. 35- 40.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Eco-Vector, 2008

Creative Commons License
Este artigo é disponível sob a Licença Creative Commons Atribuição–NãoComercial–SemDerivações 4.0 Internacional.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 84654 от 01.02.2023 г. 

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies